Biotron Ltd
ASX:BIT

Watchlist Manager
Biotron Ltd Logo
Biotron Ltd
ASX:BIT
Watchlist
Price: 0.003 AUD -25% Market Closed
Market Cap: 6.5m AUD

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
AU$0
/
AU$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
AU$0
/
AU$0

Peer Comparison

Country Company Market Cap Operating
Margin
AU
Biotron Ltd
ASX:BIT
6.5m AUD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
380.6B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
182.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
158.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.5B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...
No Stocks Found

Market Distribution

Not Available
No Country distribution data available for this multiple

Biotron Ltd
Glance View

Market Cap
6.5m AUD
Industry
Biotechnology

Biotron Ltd. operates as a clinical stage biotechnology company. The company is headquartered in North Ryde, New South Wales. The company went IPO on 2001-01-24. The firm is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The company is engaged in developing small molecule antiviral therapeutics targeting a range of viruses including Hepatitis C virus (HCV) and human immunodeficiency virus-1 (HIV-1). The firm's lead drug, BIT225 is in Phase II clinical development for the treatment of HIV-1 and HCV infections. BIT225 is a small-molecule anti-viral compound that works to inhibit the viroporin mechanism of Viral Protein U (Vpu). BIT225, in HIV-1, offers eradicate reservoirs of virus found in long-lived macrophage cells, which contribute to the need for life-long treatment with antiretroviral drugs. For HCV, BIT225 offers as a class of oral direct-acting antiviral (DAA) drug. The firm progresses its Hepatitis B virus (HBV) program. The company also designs and develops drugs drugs that target a class of viral proteins known as viroporins.

BIT Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top